Clinical pharmacology of famotidine: a summary.

Article Details

Citation

Copy to clipboard

Chremos AN

Clinical pharmacology of famotidine: a summary.

J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003.

PubMed ID

2887616 [ View in PubMed

]

Abstract

Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect in humans is inhibition of gastric acid secretion. Dose-related suppression of basal and stimulated (meal, pentagastrin) gastric acid output has been shown with oral doses of 5-40 mg. The 40 mg dose is associated with the highest inhibitory effect, the longest duration of action, and the greatest response uniformity. After oral administration, antisecretory activity begins within 1 h, reaches a maximum in 1-3 h, and lasts 10-12 h. In addition to the earlier onset of effect, intravenous famotidine is about twice as potent as oral, a result consistent with a systemic bioavailability of oral famotidine of about 43%. Studies in patients and in healthy volunteers have shown that famotidine does not affect cardiovascular, renal, endocrine, pancreatic exocrine, or gastrointestinal motility functions. Oral famotidine is incompletely absorbed, reaching peak plasma concentrations in 1-3 h. It is eliminated primarily through the kidneys (about 70%), mostly as the parent compound. Its average elimination half-life in healthy subjects is 2.8 h. Half-life is prolonged nonlinearly in patients with decreased renal function. To date, clinically important interactions with other drugs have not been described for famotidine.

DrugBank Data that Cites this Article

Drugs

Famotidine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Famotidine	Histamine H2 receptor	Protein	Humans	Yes	Antagonist	Details